AstraZeneca

AstraZeneca is a global biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers and commercializes medicines in oncology, cardiovascular, renal and metabolism, respiratory, and immunology. FDA databases, ClinicalTrials.gov, and SEC American Depositary Receipt filings document the U.S.-listed entity's portfolio.

Oncology includes Tagrisso, Imfinzi, and Lynparza, with indications listed in FDA records. Respiratory and immunology includes Symbicort and Fasenra. Cardiovascular and renal includes Farxiga. AstraZeneca's ADC and cell therapy investments appear in trial registries and SEC business descriptions.

• FDA approval records document Imfinzi and Tagrisso label expansions in lung and other solid tumors.
• SEC filings describe R&D investment levels and geographic revenue mix.
• ClinicalTrials.gov lists extensive AstraZeneca-sponsored oncology combination trials.
• Public disclosures highlight biologics manufacturing expansion plans.

AstraZeneca pipeline tables appear in annual reports and ClinicalTrials.gov registrations. Business development includes acquisitions and licensing reported in SEC 6-K filings. Use those primary sources for current phase and regulatory status.